Recombinant Human GPD1 protein

中文名： 甘油三磷酸脱氢酶1(GPD1)重组蛋白
别名： GPD1L;KIAA0089;Glycerol-3-phosphate dehydrogenase 1-like protein

货号: PA1000-1313

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>90%SDS-PAGE.
种属	Human
靶点	GPD1
Uniprot No	P21695
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	1-349aa
氨基酸序列	MASKKVCIVGSGNWGSAIAKIVGGNAAQLAQFDPRVTMWVFEEDIGGKKLTEIINTQHENVKYLPGHKLPPNVVAVPDVVQAAEDADILIFVVPHQFIGKICDQLKGHLKANATGISLIKGVDEGPNGLKLISEVIGERLGIPMSVLMGANIASEVADEKFCETTIGCKDPAQGQLLKELMQTPNFRITVVQEVDTVEICGALKNVVAVGAGFCDGLGFGDNTKAAVIRLGLMEMIAFAKLFCSGPVSSATFLESCGVADLITTCYGGRNRKVAEAFARTGKSIEQLEKELLNGQKLQGPETARELYSILQHKGLVDKFPLFMAVYKVCYEGQPVGEFIHCLQNHPEHM
预测分子量	kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是模拟生成的3篇关于GPD1重组蛋白的参考文献示例(非真实文献，供参考格式和内容方向)：

---

1. **文献名称**: *Expression and Characterization of Recombinant Human GPD1 in Escherichia coli*

**作者**: Zhang L, et al.

**摘要**: 本研究构建了人源GPD1基因的重组质粒，在大肠杆菌BL21中成功表达可溶性蛋白，并通过镍柱亲和层析纯化。酶活实验表明重组GPD1具有甘油-3-磷酸脱氢酶活性，为后续代谢疾病研究提供工具蛋白。

2. **文献名称**: *Structural Insights into GPD1 Catalytic Mechanism by Cryo-EM Analysis*

**作者**: Smith J, et al.

**摘要**: 利用冷冻电镜解析了重组GPD1蛋白的3.2Å三维结构，揭示了其NAD+结合域和底物识别关键位点，为设计针对GPD1的小分子抑制剂提供了结构基础。

3. **文献名称**: *GPD1 Overexpression Ameliorates Hepatic Steatosis in Diabetic Mouse Models*

**作者**: Wang Y, et al.

**摘要**: 通过腺病毒载体在糖尿病小鼠肝脏中过表达重组GPD1蛋白，结果显示显著降低肝脏甘油三酯积累，表明GPD1在调节脂代谢中的潜在治疗价值。

---

**说明**：以上为模拟示例，实际文献请通过PubMed、Google Scholar等平台检索关键词"GPD1 recombinant protein"或结合具体研究领域筛选。

背景信息

Glycerol-3-phosphate dehydrogenase 1 (GPD1) is a key metabolic enzyme that catalyzes the reversible conversion of dihydroxyacetone phosphate (DHAP) to glycerol-3-phosphate (G3P), linking carbohydrate and lipid metabolism. This NAD-dependent enzyme plays a dual role in energy homeostasis: in the cytoplasm, it facilitates glycerol synthesis for triglyceride storage, while in the mitochondria, it contributes to the glycerol phosphate shuttle for ATP generation. Dysregulation of GPD1 has been implicated in metabolic disorders, including obesity, diabetes, and non-alcoholic fatty liver disease, making it a potential therapeutic target.

Recombinant GPD1 protein is produced using biotechnological platforms like *E. coli* or mammalian expression systems, enabling large-scale purification for research and drug development. Its production typically involves cloning the human GPD1 gene into expression vectors, followed by affinity chromatography for isolation. Structural studies using recombinant GPD1 have revealed insights into its catalytic mechanism and regulation, while functional assays help screen modulators for metabolic disease treatment.

Beyond therapeutics, recombinant GPD1 serves as a critical tool for diagnosing inborn errors of metabolism and studying cellular redox balance. Engineered variants with modified stability or activity are also explored to optimize industrial applications, such as biofuel production. However, challenges persist in maintaining enzymatic activity post-purification and scaling production cost-effectively. Ongoing research focuses on resolving its structural dynamics and tissue-specific roles to advance translational applications.

Overall, recombinant GPD1 bridges basic science and clinical innovation, offering a versatile platform to dissect metabolic pathways and develop precision therapies.